about
sameAs
Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factorAnti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes.CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients.Erratum to: Donor age and C1orf132/MIR29B2C determine age-related methylation signature of blood after allogeneic hematopoietic stem cell transplantation.Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.Beneficial effect of the CXCL12-3'A variant for patients undergoing hematopoietic stem cell transplantation from unrelated donors.NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.Donor age and C1orf132/MIR29B2C determine age-related methylation signature of blood after allogeneic hematopoietic stem cell transplantation.The presence of functional CCR5 and EBV reactivation after allogeneic haematopoietic stem cell transplantation.Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation.IL-10 promoter polymorphisms influence susceptibility to aGvHD and are associated with proportions of CD4+FoxP3+ lymphocytes in blood after hematopoietic stem cell transplantation.The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin's lymphomaCan determination of gene polymorphism be of practical value in tailoring the treatment of HSCT patients?Donor lymphocyte infusions to leukemic bone lesions are therapeutically effective in a Ph+ ALL patient with post-HSCT relapseHLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donorThe -2549 -2567 del18 Polymorphism in VEGF and Irreversible Bronchoconstriction in AsthmaticsIntra-bone donor lymphocyte infusion at relapse: clinical outcome is associated with presence of CD8+ cells in the marrow
P50
Q33654957-F6EBD5C1-A987-4895-8D52-82371AC6093DQ35232833-234A5A89-70F5-4DCB-AF30-D568D8AD0D72Q36440010-0FE9ECDD-BC15-4DB4-BAF3-D4342279997BQ37423940-FDDCEA85-032F-408B-B885-646830C7CEC9Q39117286-2E53C546-4263-4D3D-92CB-310B7615D6F7Q41532474-C9FA8A9A-02A0-4E78-856F-17345047F7D3Q41732815-7A335D8C-AC32-407A-98B3-1704D5DDF1BCQ42248606-3886BB65-CA13-4195-89EF-FB2513B92ADEQ42397965-CA2106D0-1C6F-4DAB-8AF5-4067F9099C1FQ43513078-FBB05DE1-FC75-4F34-A5F5-0C94D7A61AC6Q45372130-D2FDAAF7-82A6-423F-9D3F-2EE7626812E1Q46812391-00583654-6F4D-4CE6-8FDF-4A4990BDDC31Q47229822-195BC0A7-1F26-4C7C-9D44-2962C7D23FC0Q48846219-B333BD95-CC1F-480F-9A3C-26D9090B487EQ51863549-65AD79DD-BBA9-428F-912A-2155F2389492Q51969662-A4ECC70E-4991-4E09-9E15-A941F43D74A1Q84535326-B9E72A1D-E980-40B6-8CEF-439F79F8C2AFQ86653462-C6897456-4530-4BC5-B8F8-31572FA9E669Q87417701-C623A2B2-178C-46FA-B4B2-FA683FBA46BDQ88236777-B9E3E2F1-565C-48CF-84FA-E8E82E37A7D6Q90688728-B3EFA945-8907-4648-AF62-E5E3D28EE101Q92914500-BD079145-2F30-4AA8-8160-6F3F559A5928
P50
description
researcher ORCID ID = 0000-0002-4894-7522
@en
wetenschapper
@nl
name
Emilia Jaskula
@ast
Emilia Jaskula
@en
Emilia Jaskula
@es
Emilia Jaskula
@nl
type
label
Emilia Jaskula
@ast
Emilia Jaskula
@en
Emilia Jaskula
@es
Emilia Jaskula
@nl
prefLabel
Emilia Jaskula
@ast
Emilia Jaskula
@en
Emilia Jaskula
@es
Emilia Jaskula
@nl
P106
P31
P496
0000-0002-4894-7522